ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO593

PBI-4547 Prevents Renal Destruction and Fibrosis in Severely Obese db/db Mouse Model of Diabetes-Induced Kidney Disease

Session Information

Category: Diabetes

  • 501 Diabetes Mellitus and Obesity: Basic - Experimental


  • Leblond, Francois A., Prometic BioSciences Inc., Laval, Quebec, Canada
  • Létourneau, Sylvie, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Ouboudinar, Jugurtha, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Gervais, Liette, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Laurin, Pierre, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Grouix, Brigitte, Prometic BioSciences Inc., Laval, Quebec, Canada
  • Gagnon, Lyne, Prometic BioSciences Inc., Laval, Quebec, Canada

Type 2 diabetes (T2D) is a major health problem worldwide. Comorbidities, such as kidney disease, associated to T2D are numerous and cause severe reduction of life expectancy. The uninephrectomized (NX) diabetic (db/db) mouse is a widely used model for the study of comorbidities associated to T2D. It also allows to study effects of obesity on diabetes-induced kidney disease. PBI-4547 is an orally active compound that displays anti-fibrotic and metabolic activities via a novel mechanism of action. The aim of this study was to investigate the protective effect of PBI-4547 on kidney health and function in NX db/db mice.


Total nephrectomy of the right kidney was performed on day 0 on 6-weeks old db/db (B6.BKS(D) and control C57BL/6 mice. Animals were treated with vehicle or PBI-4547 (25 mg/kg) from day 1 through 105 by daily oral gavage.


PBI-4547 significantly improved diabetic condition of db/db mice, and lowered weight gain to that of control C57BL/6 mice. A significant reduction of fasting blood glucose, plasma insulin, and area under the curve in oral glucose tolerance test were observed in PBI-4547-treated db/db mice. PBI-4547 dosing also resulted in a reduction of plasma triglycerides and an increase in adiponectin. Moreover, PBI-4547 eventuated a significant reduction in the renal damage observed on db/db mice as shown by histopathological analysis of kidneys. When compared to control C57BL/6 mice, kidney glomeruli, tubules and capillaries of non-treated db/db mice were found significantly damaged. These modifications were almost absent on db/db mice treated with PBI-4547. Evaluation of numerous markers of fibrosis also confirmed that PBI-4547 significantly reduced the fibrosis process in the kidney. Reduction of the mRNA expression of collagen type 1 (-40%), MCP-1 (-63%), TIMP-1 (-71%), MMP-2 (-47%) and GLEPP-1 (-13%) were shown in kidneys of PBI-4547-treated compared to untreated db/db mice. Neither BUN nor GFR were found significantly modified in the db/db non-treated mice (compared to NX C57BL/6 mice) and PBI-4547 had no impact on these parameters.


These studies suggest that, in addition to the improvement of T2D, PBI-4547 treatment precludes renal structure destruction and prevents fibrosis in the kidneys of severely obese db/db mice.


  • Commercial Support